Drawing for OTSUKA DIGITAL HEALTH

USPTO serial 97434636

OTSUKA DIGITAL HEALTH

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
O'BRIEN, JENNIFER LYNN
Law office
TMO LAW OFFICE 121 - EXAMINING ATTORNEY ASSIGNED

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with OTSUKA DIGITAL HEALTH?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Scott S. Havlick

Scott S. Havlick HOLLAND & HART LLPP.O. BOX 8749ATTN: TRADEMARK DOCKETINGDENVER, CO 80201

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations, namely, pills, tablets, capsules, and caplets consisting primarily of prescription and non-prescription medicines and also including integrated circuits, microchips and silicon chips, for the treatment of and prevention of central nervous system diseases and disorders, hyponatremia, and for inhibiting blood platelet aggregationACTIVE—
009Silicon chips; downloadable computer programs for use in collecting, managing, analyzing, storing, sharing, and comparing medical information, patient records, and patient data; electronic and optical communications instruments and components, namely, digital transmitters and optical receivers for use in transmitting and receiving dataACTIVE—
010Drug delivery devices sold empty, namely, ingestible silicon chips specially adapted for use in medical diagnosis and treatment; Medical diagnostic apparatus in the nature of patches and ingestible tablets sold without medication containing silicon chips specially adapted for medical use for use collecting, transmitting and storing patient data and medical information for the diagnosis of medical conditions, namely for testing drug ingestion information, pulse, heart rate, respiratory rate, body temperature, electric pressure in the body, human motion, human position, or sleeping condition; microsensors and electric, infrared and optical communications instruments and devices to be ingested or worn by patients for use collecting, transmitting and storing patient data and medical information for the diagnosis of medical conditions, namely, sensors for medical use to be worn by a human to gather human biometric data sold as a unit; Medical products, namely, micro biofeedback sensors for measurement of human data, namely, heart rate, respiratory rate, body temperature, electric pressure in the body, human motion, human position or sleeping conditionACTIVE—
035Maintaining patient medical records and filesACTIVE—
042Providing temporary use of non-downloadable computer programs for use in collecting, managing, analyzing, storing, sharing, and comparing medical information, patient records, and patient dataACTIVE—
044Providing medical information, consultancy and advisory services; collecting, managing, analysis, storing and comparing medical information, patient records and patient data; providing guidance and advice on health management using databases used for the collection, management, analysis, accumulation, sharing and comparison of medical information, patient records and patient dataACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Nov 14, 2023MAB2ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Nov 14, 2023MAB2ABANDONMENT NOTICE MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Nov 14, 2023ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Jul 7, 2023GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 7, 2023GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 7, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 16, 2023TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 15, 2023CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 15, 2023TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 2, 2022GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 2, 2022GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 2, 2022CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 21, 2022DOCKASSIGNED TO EXAMINER—
Jun 6, 2022NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 2, 2022NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance